Newsroom

Blog

Talking Cancer: Conversation with Ultramarathoner, Triathlete, Mother, Wife, Business Owner and Overachiever, Isabella de la Houssaye

To say Isabella de la Houssaye is an overachiever, would be minimizing what she is—a triathlete, a climber, a marathoner, a long-distance runner, a mother, wife and business owner, she epitomizes a

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Using Real-World Lab Data Insights to Improve Biomarker Testing in Lung Cancer

As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted ther

Read More
Written By:
DerekLyle.jpeg
Derek Lyle

First CDx Approval for HLA Typing

We have seen HLA typing become more prominent in oncology clinical studies. Especially in the realm of immuno-oncology therapeutics including CAR T-cells, bi-specifics, and cancer vaccines.

Read More
Written By:
scottreid.jpg
Scott Reid

Talking Cancer Blog: A Conversation with Holly Smithson, Athena CEO & Diversity Champion

Written By:
MadhuGhosh.jpg
Madhu Ghosh

ISO 15189 accreditation of the Swiss and Singapore NeoGenomics sites

In 2020 NeoGenomics decided to launch an accreditation program for its international sites in Switzerland and Singapore.

Read More
Written By:
Charlotte Serra profile image
Charlotte Serra

Entering the Multi-omics and precision medicine era in cancer research

Why multi-omics?

Cancer hallmarks typically incorporate complex phenotypic and molecular changes including uncontrolled and sustained proliferation, evading growth suppressors, resisting

Read More
Written By:
QinqinZha.jpg
Qinqin Zha

The Story, The Patient, The Activist

We wanted to start 2022 by reinforcing NeoGenomics Laboratories, Inc.’s promise to work toward state-of-the-art diagnostic and oncology testing for patients.

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Perspectives on a ssPMA CDx submission

The proprietary, high sensitivity Sanger sequencing assay (LOD <1%), developed by NeoGenomics, was used in certain BeiGene Phase 2 and Phase 3 clinical studies to determine the MYD88 status of p

Read More
Written By:
scottreid.jpg
Scott Reid

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients